Celcuity Q3 Loss Narrower Than Expected as Launch Spending Runs $77.3M
CELC sits 20% above its 52-week low of $53.54.
Summary
Celcuity posted a Q3 adjusted loss of $1.21 per share, well inside the $1.43 IBES consensus, with adjusted net loss of $66.8 million versus an $82.2 million estimate. Reported net loss was $73.3 million and EPS -$1.33, with operating expenses at $77.3 million. The beat comes as the company funds the U.S. commercial rollout of REVTORPYK (gedatolisib), which became commercially available September 30 following the August sNDA filing in PIK3CA-mutant advanced breast cancer. The $754 million cash position disclosed with Q2 results gives runway into 2029, so this quarter's spend rate is the number to track against that guidance.
At the time of this announcement, CELC was trading at $64.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $53.54 to $151.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.